Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease

Haematologica

Volumn 88, Issue 7, 2003, Pages 837-839

  Busca, Alessandro ^a   Locatelli, Franco ^a   Marmont, Filippo ^a   Audisia, Ernesta ^a   Falda, Michele ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ARTICLE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MUSCLE CRAMP; NAUSEA; TREATMENT OUTCOME; VOMITING;

ADULT; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; NEOPLASMS; TREATMENT OUTCOME;

EID: 0038376700     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Basara N, Blau WI, Kiehl MG, Römer E, Rudolphi M, Bischoff M, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipients. Transplant Proceed 1998;30:4087-9.
2. Bornhauser M, Schuler U, Pörksen G, Naumann R, Geissler G, Thiede C, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999;67:499-504.
3. Mookerjee B, Altomonte V, Vogelsang. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999;24:517-20.
4. Busca A, Sbroglia EM, Lanino E, Manfredini L, Uderzo C, Nicolini B, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000;25:1067-71.
5. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002;30:287-95.